VJHemOnc Podcast cover image

Key HemOnc updates from ASCO 2025: myeloma, lymphoma, MPNs, & more!

VJHemOnc Podcast

00:00

Long-Term Progression-Free Survival in 17p Deletion CLL

This chapter reviews the five-year follow-up results from the Sequoia trial, showcasing the impressive 72.2% progression-free survival rate for patients with deletion 17p CLL treated with zanabrutinib. It also explores future research avenues to improve patient outcomes through innovative treatment strategies.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app